{"url_path":"/sec/rgnx/8-k/2026-05-14/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-222768-index.html","accession_number":"0001193125-26-222768","cik":"0001590877","ticker":"RGNX","issuer_name":"REGENXBIO Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590877/0001193125-26-222768-index.html","primary_entity_key":"0001590877","primary_entity_name":"REGENXBIO Inc."},"word_count":56,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\nOn May 14, 2026, the Company issued a press release announcing topline and interim analysis of data from the AFFINITY DUCHENNE RGX-202 trial (the “RGX-202 Press Release”). A copy of the RGX-202 Press Release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein."}